CORDIS
EU research results

CORDIS

English EN

Use of PRIMate MOdels to support translational MEDicine and advance disease modifying therapies for unmet medical needs

Project information

Grant agreement ID: 606084

Status

Closed project

  • Start date

    1 January 2014

  • End date

    30 September 2015

Funded under:

FP7-SME

  • Overall budget:

    € 1 602 769

  • EU contribution

    € 1 234 000

Coordinated by:

AMAKEM NV

Belgium

Objective

The focus of Primomed is the translational medicinal approach of the SMEs, i.e. developing disease modifying therapeutics for high unmet medical needs in chronic inflammatory and degenerative disorders. The Primomed project utilizes well characterized non-human primate models so that the SMEs can capitalize on subsequent clinical successes of their therapeutic lead compounds. The main objectives of the project are (1) to demonstrate proof of concept that drug compounds of the SME’s are efficacious in primate models relevant for the diseases of interest and (2) to determine the immune responses in biological samples generated by the research activities in the different animal models. The power of the Primomed project is the creation of a consortium bringing together four small and early-stage biotech companies owning innovative and proprietary drugs and two of the most renowned European primate research centres that will perform research activities with the new disease modifying molecules of the SME’s.
The disease areas of interest in Primomed are asthma, multiple sclerosis and Parkinson disease. Amakem’s Localized Drug Action approach would allow the use of ROCK inhibitors for the treatment of respiratory diseases, e.g. asthma, while avoiding the side effects resulting from systemic ROCK inhibition. By selectively targeting IL-23p19, Complix’ Alphabody is an intriguing candidate for therapy development of asthma and MS and may avoid some of the severe side effects of other currently available and tested anti-IL12/IL23p40 therapies. FFP’s PG102 would be a first in class molecule with a novel mechanism of action in treating chronic inflammatory conditions such as MS. sNRG would be a protein drug with disease modifying potential for the treatment of an unmet medical need in Parkinson’s disease.
Primomed will result in progressing the compounds to the clinic, maximize the chance at eventual market authorization and answer the unmet medical need of millions of patients.

Coordinator

AMAKEM NV

Address

Agoralaan Gebouw Abis Bioville
3590 Diepenbeek

Belgium

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 320 235

Administrative Contact

Jack Veuskens (Dr.)

Participants (5)

COMPLIX NV

Belgium

EU Contribution

€ 374 599

FAST FORWARD PHARMACEUTICALS BV

Netherlands

EU Contribution

€ 172 616

MIND-NRG SA

Switzerland

EU Contribution

€ 354 550

STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

Netherlands

EU Contribution

€ 6 000

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 6 000

Project information

Grant agreement ID: 606084

Status

Closed project

  • Start date

    1 January 2014

  • End date

    30 September 2015

Funded under:

FP7-SME

  • Overall budget:

    € 1 602 769

  • EU contribution

    € 1 234 000

Coordinated by:

AMAKEM NV

Belgium